Improved SARS-CoV-2 Neutralization of Delta and Omicron BA.1 Variants of Concern after Fourth Vaccination in Hemodialysis Patients.
Improved SARS-CoV-2 Neutralization of Delta and Omicron BA.1 Variants of Concern after Fourth Vaccination in Hemodialysis Patients.
复制标题
DOI：
10.3390/vaccines10081328
复制
发表时间：
2022-08-16
期刊：
影响因子：
7.8
通讯作者：
Braunisch, Matthias Christoph
中科院分区：
文献类型：
--
作者：
Cheng, Cho-Chin;Platen, Louise;Christa, Catharina;Tellenbach, Myriam;Kappler, Verena;Bester, Romina;Liao, Bo-Hung;Holzmann-Littig, Christopher;Werz, Maia;Schonhals, Emely;Platen, Eva;Eggerer, Peter;Treguer, Laetitia;Kuchle, Claudius;Schmaderer, Christoph;Heemann, Uwe;Renders, Lutz;Protzer, Ulrike;Braunisch, Matthias Christoph
血液透析患者感染SARS-CoV-2的风险明显增加。迄今为止，尚不清楚血液透析患者是否能从四种疫苗中获益。截止到2022年3月，共有142名血液透析患者接受了4次新冠病毒疫苗接种。RDB结合抗体滴度在竞争性替代中和试验中测定。Vero-E6细胞感染了SARS-CoV-2关注（VoC）、Delta （B.1.617.2）或Omicron （B.1.1.529，亚谱系BA.1）变体，以测定血清感染中和能力。与第三次接种后4个月相比，第4次接种后4周，血清感染中和能力从50%抑制浓度（IC50，血清稀释因子1:x）的247.0（46.3-1560.8）显著增加到2560.0 (1174.0-2560.0)，Omicron VoC从37.5（20.0-198.8）显著增加到668.5 (182.2-2560.0)（p均< 0.001）。在三次疫苗接种后，甚至观察到高抗体滴度患者的中和能力显著增加（p < 0.001）。10例首次采血后出现SARS-CoV-2突破感染的患者，其先前对Omicron的中和能力呈下降趋势（p = 0.051）。我们的研究结果表明，血液透析患者受益于第四次疫苗接种，特别是考虑到高度传染性的SARS-CoV-2 ommicron变体。常规接种四次疫苗似乎可以扩大对变异的免疫力，建议血液透析患者接种。
Hemodialysis patients are exposed to a markedly increased risk when infected with SARS-CoV-2. To date, it is unclear if hemodialysis patients benefit from four vaccinations. A total of 142 hemodialysis patients received four COVID-19 vaccinations until March 2022. RDB binding antibody titers were determined in a competitive surrogate neutralization assay. Vero-E6 cells were infected with SARS-CoV-2 variants of concern (VoC), Delta (B.1.617.2), or Omicron (B.1.1.529, sub-lineage BA.1) to determine serum infection neutralization capacity. Four weeks after the fourth vaccination, serum infection neutralization capacity significantly increased from a 50% inhibitory concentration (IC50, serum dilution factor 1:x) of 247.0 (46.3–1560.8) to 2560.0 (1174.0–2560.0) for the Delta VoC, and from 37.5 (20.0–198.8) to 668.5 (182.2–2560.0) for the Omicron VoC (each p < 0.001) compared to four months after the third vaccination. A significant increase in the neutralization capacity was even observed for patients with high antibody titers after three vaccinations (p < 0.001). Ten patients with SARS-CoV-2 breakthrough infection after the first blood sampling had by trend lower prior neutralization capacity for Omicron (p = 0.051). Our findings suggest that hemodialysis patients benefit from a fourth vaccination in particular in the light of the highly infectious SARS-CoV-2 Omicron-variants. A routinely applied four-time vaccination seems to broaden immunity against variants and would be recommended in hemodialysis patients.
登录
查看更多内容
DOI：
10.3390/diagnostics11101757
发表时间：
2021-09-24
期刊：
Diagnostics (Basel, Switzerland)
影响因子：
--
作者：
Chan KH;Leung KY;Zhang RR;Liu D;Fan Y;Chen H;Yuen KY;Hung IF
通讯作者：
Hung IF
DOI：
10.2215/cjn.10300721
发表时间：
2022-02-10
影响因子：
9.8
作者：
El Karoui, Khalil;Hourmant, Maryvonne;EIN Registry
通讯作者：
EIN Registry
影响因子：
64.5
作者：
Garcia-Beltran, Wilfredo F.;St Denis, Kerri J.;Balazs, Alejandro B.
通讯作者：
Balazs, Alejandro B.
影响因子：
11.8
作者：
Erber J;Kappler V;Haller B;Mijočević H;Galhoz A;Prazeres da Costa C;Gebhardt F;Graf N;Hoffmann D;Thaler M;Lorenz E;Roggendorf H;Kohlmayer F;Henkel A;Menden MP;Ruland J;Spinner CD;Protzer U;Knolle P;Lingor P;SeCoMRI Study Group2
通讯作者：
SeCoMRI Study Group2
影响因子：
2.3
作者：
通讯作者：
--